The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs

Jeroen J. M. Hoozemans; M. Kerry O'Banion

doi:https://doi.org/10.2174/1568007054038201

The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs

Jeroen J. M. Hoozemans, M. Kerry O'Banion

Research output: Contribution to journal › Article › Academic › peer-review

97 Citations (Scopus)

Abstract

Epidemiological studies indicate that anti-inflammatory drugs, especially the non-steroidal anti-inflammatory drugs (NSAIDs), decrease the risk of developing Alzheimer's disease (AD). Their beneficial effects may be due to interference of the chronic inflammatory reaction in AD. The best-characterised action of NSAIDs is the inhibition of cyclooxygenase (COX). So far, clinical trials designed to inhibit inflammation or cyclooxygenase activity have failed in the treatment of AD patients. In this review we will focus on the role, expression and regulation of COX-1 and COX-2 in neurodegeneration and AD pathogenesis. Understanding the pathological, physiological and neuroprotective role of cyclooxygenase will contribute to the development of a therapy for the treatment or prevention of AD

Original language	English
Pages (from-to)	307-315
Number of pages	9
Journal	Current drug targets
Volume	4
Issue number	3
DOIs	https://doi.org/10.2174/1568007054038201
Publication status	Published - 1 Jun 2005

Keywords

Alzheimer's disease
COX-1
COX-2
Microglia
NSAIDs
Neuroinflammation
Neuron

Access to Document

https://doi.org/10.2174/1568007054038201

Cite this

@article{886e4e827ab04b3ea36a313657943b02,

title = "The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs",

abstract = "Epidemiological studies indicate that anti-inflammatory drugs, especially the non-steroidal anti-inflammatory drugs (NSAIDs), decrease the risk of developing Alzheimer's disease (AD). Their beneficial effects may be due to interference of the chronic inflammatory reaction in AD. The best-characterised action of NSAIDs is the inhibition of cyclooxygenase (COX). So far, clinical trials designed to inhibit inflammation or cyclooxygenase activity have failed in the treatment of AD patients. In this review we will focus on the role, expression and regulation of COX-1 and COX-2 in neurodegeneration and AD pathogenesis. Understanding the pathological, physiological and neuroprotective role of cyclooxygenase will contribute to the development of a therapy for the treatment or prevention of AD",

keywords = "Alzheimer's disease, COX-1, COX-2, Microglia, NSAIDs, Neuroinflammation, Neuron",

author = "Hoozemans, {Jeroen J. M.} and O'Banion, {M. Kerry}",

year = "2005",

month = jun,

day = "1",

doi = "https://doi.org/10.2174/1568007054038201",

language = "English",

volume = "4",

pages = "307--315",

journal = "Current drug targets",

issn = "1389-4501",

publisher = "Bentham Science Publishers B.V.",

number = "3",

}

TY - JOUR

T1 - The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs

AU - Hoozemans, Jeroen J. M.

AU - O'Banion, M. Kerry

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Epidemiological studies indicate that anti-inflammatory drugs, especially the non-steroidal anti-inflammatory drugs (NSAIDs), decrease the risk of developing Alzheimer's disease (AD). Their beneficial effects may be due to interference of the chronic inflammatory reaction in AD. The best-characterised action of NSAIDs is the inhibition of cyclooxygenase (COX). So far, clinical trials designed to inhibit inflammation or cyclooxygenase activity have failed in the treatment of AD patients. In this review we will focus on the role, expression and regulation of COX-1 and COX-2 in neurodegeneration and AD pathogenesis. Understanding the pathological, physiological and neuroprotective role of cyclooxygenase will contribute to the development of a therapy for the treatment or prevention of AD

AB - Epidemiological studies indicate that anti-inflammatory drugs, especially the non-steroidal anti-inflammatory drugs (NSAIDs), decrease the risk of developing Alzheimer's disease (AD). Their beneficial effects may be due to interference of the chronic inflammatory reaction in AD. The best-characterised action of NSAIDs is the inhibition of cyclooxygenase (COX). So far, clinical trials designed to inhibit inflammation or cyclooxygenase activity have failed in the treatment of AD patients. In this review we will focus on the role, expression and regulation of COX-1 and COX-2 in neurodegeneration and AD pathogenesis. Understanding the pathological, physiological and neuroprotective role of cyclooxygenase will contribute to the development of a therapy for the treatment or prevention of AD

KW - Alzheimer's disease

KW - COX-1

KW - COX-2

KW - Microglia

KW - NSAIDs

KW - Neuroinflammation

KW - Neuron

UR - http://www.scopus.com/inward/record.url?scp=19944363180&partnerID=8YFLogxK

U2 - https://doi.org/10.2174/1568007054038201

DO - https://doi.org/10.2174/1568007054038201

M3 - Article

C2 - 15975032

SN - 1389-4501

VL - 4

SP - 307

EP - 315

JO - Current drug targets

JF - Current drug targets

IS - 3

ER -

The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs

Abstract

Keywords

Access to Document

Other files and links

Cite this